Nanobiotix S.A. (LON:0QAV)
18.80
-0.14 (-0.74%)
At close: Dec 17, 2025
Nanobiotix Revenue
Nanobiotix had revenue of 13.32M EUR in the half year ending June 30, 2025, with 186.77% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M.
Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
91.52
Revenue / Employee
94.06K EUR
Employees
108
Market Cap
797.00M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.10% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -243.00K | -6.53% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.35% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 1.18M | 73.67% |
| Dec 31, 2013 | 1.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Nanobiotix News
- 8 hours ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 2 days ago - NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris - GlobeNewsWire
- 23 days ago - Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewsWire
- 23 days ago - Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue - The Motley Fool
- 4 weeks ago - NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations - GlobeNewsWire
- 6 weeks ago - NANOBIOTIX to Participate in Investor Conferences the Week of November 10th - GlobeNewsWire
- 6 weeks ago - Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty - GuruFocus
- 6 weeks ago - NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth - GlobeNewsWire